Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.22/5390
Título: Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome
Autor: Camilo, Vânia
Barros, Rita
Celestino, Ricardo
Castro, Patrícia
Vieira, Joana
Teixeira, Manuel R
Carneiro, Fátima
Pinto-de-Sousa, João
David, Leonor
Almeida, Raquel
Palavras-chave: SOX2
CDX2
Gastric cancer
Prognosis
Survival
Data: 9-Out-2014
Editora: Dafne Solera
Resumo: Background Gastric cancer remains a serious health concern worldwide. Patients would greatly benefit from the discovery of new biomarkers that predict outcome more accurately and allow better treatment and follow-up decisions. Here, we used a retrospective, observational study to assess the expression and prognostic value of the transcription factors SOX2 and CDX2 in gastric cancer. Methods SOX2, CDX2, MUC5AC and MUC2 expression were assessed in 201 gastric tumors by immunohistochemistry. SOX2 and CDX2 expression were crossed with clinicopathological and follow-up data to determine their impact on tumor behavior and outcome. Moreover, SOX2 locus copy number status was assessed by FISH (N = 21) and Copy Number Variation Assay (N = 62). Results SOX2 was expressed in 52% of the gastric tumors and was significantly associated with male gender, T stage and N stage. Moreover, SOX2 expression predicted poorer patient survival, and the combination with CDX2 defined two molecular phenotypes, SOX2+CDX2- versus SOX2-CDX2+, that predict the worst and the best long-term patients’ outcome. These profiles combined with clinicopathological parameters stratify the prognosis of patients with intestinal and expanding tumors and in those without signs of venous invasion. Finally, SOX2 locus copy number gains were found in 93% of the samples reaching the amplification threshold in 14% and significantly associating with protein expression. Conclusions We showed, for the first time, that SOX2 combined with CDX2 expression profile in gastric cancer segregate patients into different prognostic groups, complementing the clinicopathological information. We further demonstrate a molecular mechanism for SOX2 expression in a subset of gastric cancer cases.
Peer review: yes
URI: http://hdl.handle.net/10400.22/5390
DOI: 10.1186/1471-2407-14-753
Versão do Editor: http://www.biomedcentral.com/content/pdf/1471-2407-14-753.pdf
Aparece nas colecções:ESS - APCT - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Camilo_V_2014_SOX2_gastric_cancer.pdf1,55 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.